fallback.jpg

Company Overview

Who We Are

BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicines.

Elion, the BioSymetrics platform, uses machine learning to connect data sources – including patient data from millions of electronic medical records and experimental data captured in zebrafish models using proprietary computer vision – to identify high-confidence targets for drug discovery. Targets discovered using BioSymetrics’ platform are grounded in human genetic evidence, giving them twice the likelihood of clinical success. BioSymetrics is advancing programs in cardiometabolic, neurological, and rare diseases, including familial dilated cardiomyopathy, atherosclerosis, and epilepsy.

We are a remote-first company with people clusters in Boston, Toronto, and San Francisco.

What We Do

Co-Founder and Chief Scientific Officer, Gabe Musso, provides an overview of BioSymetrics and our lead Epilepsy program at the 2023 Broad Institute Machine Learning in Drug Discovery Symposium.

 

Technology

Our team is a diverse group of proven entrepreneurs, machine learning experts and R&D innovators. Our Advisory Board includes renowned scientists and technologists each with highly relevant expertise to our vision to advance precision medicines using data, machine learning and in vivo validation.
View Our Team